Dec. 11, 2025 -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company, announced today that its next-generation TRK inhibitor, zurletrectinib (ICP-723), has received approval from the China National Medical Products Administration (NMPA) for the treatment of adult and adolescent patients (aged 12 years and older) with solid tumors harboring NTRK gene fusions. In the registrational clinical trial for patients with NTRK fusion-positive solid tumors, zurletrectinib demo

Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial KT-621 BROADEN2 Phase 2b AD trial ongoing, with data expected to be reported by mid-2027 and BREADTH Phase 2b trial in asthma on track to initiate in 1Q26 Dec. 11, 2025 -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the

OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development Strategic Amendment Enhances OSE Immunotherapeutics’ Role in ABBV-230 Development While Preserving AbbVie’s Long-Term Commitment December 8th, 2025 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced an amendment to its partnership agreement with AbbVie regarding ABBV-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently i

Proceeds to further advance clinical development of BH-30643, a first-in-class, macrocyclic, CNS-active, mutant-selective OMNI-EGFRTM inhibitor for EGFR-mutant NSCLC, and BH-30236, a novel macrocyclic CLK inhibitor targeting aberrant RNA splicing Financing includes participation from leading institutional investors including Janus Henderson Investors, Brahma Capital, Biotrack Capital, Cormorant Asset Management, OrbiMed, Plaisance Capital Management LLC and Vivo Capital Dec. 10, 2025 -- Blosso

Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first significant endocrine therapy advance in over 20 years1-3 Transformational results support the potential of giredestrant to become a new standard-of-care for early-stage disease1 ER-positive breast cancer accounts for approximately 70% of breast cancer cases, and up to a third experience recurrence on or after adjuvant endocrine therapy treatment4-7 Data will be featured

$47.5 million Series A financing led by Samsara Biocapital and Lightstone Ventures to advance PsiThera’s growing pipeline, starting with multiple clinically validated TNF superfamily preclinical programs Biotech veteran Eric Shaff appointed CEO and joins established leadership team, including Woody Sherman, Ph.D., Founder and Chief Innovation Officer, and Camil Sayegh, Ph.D., Chief Scientific Officer PsiThera’s scientific approach and QUAISAR™ platform, integrating molecular dynamics with artifi

Newton Biocapital enters as new investor, strong participation of existing investors Pivotal Phase 2b trial initiation in 2027 of BIOX-101 to treat intracerebral hemorrhage BIOX-101 may be commercialized as early as H2 2030 10 December 2025 (08:30 am CET) – Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases, has raised €5.5 million in a Series A extension funding round, enabling the company

The approval marks the first new treatment option for people living with progressive pulmonary fibrosis (PPF) in more than five years. PPF is a rare lung condition, more life-threatening than many forms of cancer, causing a continuous decline in lung function.1,2,3 PPF is the second approved indication in China for nerandomilast, following recent approvals in the U.S. and China for the treatment of idiopathic pulmonary fibrosis (IPF).4,5 China’s National Medical Products Administration (NMPA) h

Dec. 10, 2025 -- Ajax Therapeutics, Inc., a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to AJ1-11095 for the treatment of myelofibrosis, a debilitating blood cancer that affects approximately 20,000 patients in the U.S. AJ1-11095 is the first JAK2 inhibitor to enter the clinic that binds the Type II conformation of th

RMAT designation indicates that SENTI-202 has the potential to address unmet medical needs for patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) based on preliminary clinical evidence, and offers benefits of FDA working closely with Senti Bio to provide guidance and advice on generating the data needed to support approval of the product in an efficient manner Second FDA designation for SENTI-202 this year, after Orphan Drug Designation, is supported by clinical data showing de